Lavoltidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lavoltidine
Lavoltidine.svg
Systematic (IUPAC) name
[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number 76956-02-0
ATC code none
PubChem CID 55473
ChemSpider 50093
UNII X16K5179V5
Chemical data
Formula C19H29N5O2
Molar mass 359.47 g/mol

Lavoltidine (INN,[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[3][4]

See also[edit]

References[edit]

  1. ^ "WHO Drug Information. Vol 4, No. 3, 1990. International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). World Health Organization. p. 7. Retrieved 12 January 2016. 
  2. ^ "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016. 
  3. ^ Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7. 
  4. ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.